Advances in the management of glioblastoma: The role of temozolomide and MGMT testing

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue 1, 2012, Pages 1-9

  Thomas, Reena P ^a   Recht, Lawrence ^a   Nagpal, Seema ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; MGMT; PredictMDx ; Temozolomide

Indexed keywords

CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; AGE DISTRIBUTION; APLASTIC ANEMIA; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENETIC SCREENING; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LIVER FAILURE; MOLECULAR DIAGNOSIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

EID: 84871883687     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S26586     Document Type: Review

References (70)

1. Howlader NA, Noone AM, Krapcho M, et al; National Cancer Institute. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). 2011 [Updated August 20, 2012]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed November 19, 2012.
2. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985;56(5):1106-1111.
3. Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: Primary Brain and Central Nervous System Diagnosed in the United States in 2004-2007. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2011. Available from: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. Accessed November 19, 2012.
4. Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA. 1972;222(5):549-552.
5. Wilson CB, Gutin P, Boldrey EB, Drafts D, Levin VA, Enot KJ. Single-agent chemotherapy of brain tumors. A five-year review. Arch Neurol. 1976;33(11):739-744.
6. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52(6):997-1007.
7. Solero CL, Monfardini S, Brambilla C, et al. Controlled study with BCNU vs CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials. 1979;2(1):43-48.
8. Stevens MF, Newlands ES. From triazines and triazenes to temozolomide. Eur J Cancer. 1993;29A(7):1045-1047.
9. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23(1):35-61.
10. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9):494-503.
11. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-6899.
12. National Toxicology Program. Final report on carcinogens background document for formaldehyde. Rep Carcinog Backgr Doc. 2010;10-5981: i-512.
13. Deltour I, Auvinen A, Feychting M, et al. Mobile phone use and incidence of glioma in the Nordic countries1979-2008: consistency check. Epidemiology. 2012;23(2):301-307.
14. Little MP, Rajaraman P, Curtis RE, et al. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ. 2012;344:e1147.
15. Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in glioblastoma? Clin Cancer Res. 2011;17(14):4619-4621.
16. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325(19):1330-1336.
17. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3(4):523-530.
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
19. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
20. Tentori L, Orlando L, Lacal PM, et al. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol. 1997;52(2):249-258.
21. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26(2):186-197.
22. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999;17(8):2604-2613.
23. Park DM, Shah DD, Egorin MJ, Beumer JH. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol. 2009;93(2):279-283.
24. Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 1999;10(7):831-838.
25. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10(11):3728-3736.
26. Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5(2):309-317.
27. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65(2):287-291.
28. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940-942.
29. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484-488.
30. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588-593.
31. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58(19):4363-4367.
32. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375-1382.
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
34. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988;(6):279-284.
35. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(12):937-944.
36. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11(1):69-79.
37. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol. 2011;29:2006.
38. Temodar® [prescribing information]. Whitehouse Station, NJ: Merck and Co, Inc; 2012.
39. Oh J, Kutas GJ, Davey P, Morrison M, Perry JR. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol. 2010;17(4):124-126.
40. Sarma N. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol. 2009;10(4):264-267.
41. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
42. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18-24.
43. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178-1182.
44. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570-4574.
45. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
46. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
47. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. Epub ahead of print, August 25, 2012.
48. Hayashi H, Saito Y, Kokuho N, et al. Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. Jpn J Clin Oncol. 2012;42(7):632-636.
49. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4(2):426-428.
50. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74(7):730-734.
51. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199.
52. Uno M, Oba-Shinjo SM, Camargo AA, et al. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo). 2011;66(10):1747-1755.
53. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16(1):59-65.
54. Kishida Y, Natsume A, Toda H, et al. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumour Biol. 2012;33(2):373-381.
55. Georgiadis P, Polychronaki N, Kyrtopoulos SA. Progress in high-throughput assays of MGMT and APE1 activities in cell extracts. Mutat Res. 2012;736(1-2):25-32.
56. Kim YS, Kim SH, Cho J, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys. 2012;84(3):661-667.
57. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol. 2011;102(2):311-316.
58. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10(4):332-337.
59. Havik AB, Brandal P, Honne H, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012;10:36.
60. Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 2012;7(3): e33449.
61. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-2197.
62. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051-2057.
63. Recinos VR, Tyler BM, Bekelis K, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery. 2010;66(3):530-537.
64. Dong J, Zhou G, Tang D, et al. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. J Cancer Res Clin Oncol. 2012;138(12):2079-2084.
65. Patil R, Portilla-Arias J, Ding H, et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm Res. 2010;27(11):2317-2329.
66. Fujita M, Lee BS, Khazenzon NM, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(β-L-malic acid). J Control Release. 2007;122(3):356-363.
67. Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J Microencapsul. 2011;28(1):21-28.
68. Friedman HS, Kokkinakis DM, Pluda J, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998;16(11):3570-3575.
69. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27(8):1262-1267.
70. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med. 2012;4(133):133ra57.